The application of HER2-ADC in future: More than expression

Jiawei Zhou; Hanqing He; Shuhang Wang; Ning Li

doi:10.1016/j.medj.2024.01.001

The application of HER2-ADC in future: More than expression

Med. 2024 Mar 8;5(3):173-175. doi: 10.1016/j.medj.2024.01.001.

Authors

Jiawei Zhou¹, Hanqing He¹, Shuhang Wang², Ning Li³

Affiliations

¹ Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
² Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: wangshuhang@cicams.ac.cn.
³ Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: lining@cicams.ac.cn.

PMID: 38460494
DOI: 10.1016/j.medj.2024.01.001

Abstract

We analyzed the potential of HER2-targeted antibody-drug conjugates (ADCs) in treating NSCLC with activating HER2 mutations. We identified specific mutations, notably G776delinsVC, that are associated with higher therapeutic response rates, suggesting a refined approach for precision treatment. Further validation and exploration are crucial for potential breakthroughs in ADC therapy.

Publication types

Letter

MeSH terms

Antineoplastic Agents* / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / therapy
Cell Line, Tumor
Immunoconjugates* / therapeutic use
Receptor, ErbB-2 / genetics
Receptor, ErbB-2 / metabolism
Trastuzumab / therapeutic use

Substances

Antineoplastic Agents
Immunoconjugates
Receptor, ErbB-2
Trastuzumab